Dr. Reddy's Laboratories Ltd. (RDY)

37.72
0.60 1.57
NYSE : Health Technology
Prev Close 38.32
Open 38.01
Day Low/High 37.70 / 38.04
52 Wk Low/High 29.00 / 42.82
Volume 68.97K
Avg Volume 155.90K
Exchange NYSE
Shares Outstanding 166.06M
Market Cap 6.39B
EPS 1.60
P/E Ratio 23.37
Div & Yield 0.29 (0.71%)
Dr. Reddy’s Announces The Launch Of Sumatriptan Injection USP, Autoinjector System

Dr. Reddy’s Announces The Launch Of Sumatriptan Injection USP, Autoinjector System

Dr. Reddy’s Laboratories (NYSE: RDY) announced yesterday that it has launched Sumatriptan Injection USP, Autoinjector System 6 mg/0.

New Lifetime High For Dr. Reddy Laboratories (RDY)

New Lifetime High For Dr. Reddy Laboratories (RDY)

Trade-Ideas LLC identified Dr. Reddy Laboratories (RDY) as a new lifetime high candidate

3 Stocks Pushing The Drugs Industry Downward

3 Stocks Pushing The Drugs Industry Downward

TheStreet highlights 3 stocks pushing the drugs industry lower today.

Dr. Reddy Laboratories Ltd. Stock Downgraded (RDY)

Dr. Reddy Laboratories Ltd. Stock Downgraded (RDY)

Dr. Reddy Laboratories (NYSE:RDY) has been downgraded by TheStreet Ratings from from a buy to hold.

Ratings Changes Today

Upgrades: CEB, DAC, FARM, GIG, JOEZ, LGND, QDEL, RGC, RLOC, VCO, WSH Downgrades: AWRE, BNNY, CALX, ETR, GTS, HUN, ICE, NTT, PLOW, RDY Initiations: RXII Read on to get TheStreet Quant Ratings' detailed report:

Dr. Reddy’s Q3 & 9 Months FY14 Financial Results

Dr. Reddy’s Q3 & 9 Months FY14 Financial Results

Dr. Reddy’s Laboratories Ltd.

New Lifetime High For Dr. Reddy Laboratories (RDY)

New Lifetime High For Dr. Reddy Laboratories (RDY)

Trade-Ideas LLC identified Dr. Reddy Laboratories (RDY) as a new lifetime high candidate

Dr. Reddy's To Release Q3 FY14 Results On February 11, 2014

Dr. Reddy's To Release Q3 FY14 Results On February 11, 2014

Dr. Reddy's Laboratories (NYSE: RDY) will announce results for the Third Quarter ended December 31, 2013 on Tuesday, February 11, 2014 after the Board Meeting.

Dr. Reddy’s Q2 & H1 FY14 Financial Results

Dr. Reddy’s Q2 & H1 FY14 Financial Results

Dr. Reddy’s Laboratories Ltd.

Dr. Reddy's To Release Q2 And Half Year FY14 Results On October 31, 2013

Dr. Reddy's To Release Q2 And Half Year FY14 Results On October 31, 2013

Dr. Reddy's Laboratories (NYSE: RDY) will announce results for the Second Quarter and Half Year ended September 30, 2013 on Thursday, October 31, 2013 after the Board Meeting.

Dr. Reddy’s Announces The Approval Of Azacitidine For Injection

Dr. Reddy’s Announces The Approval Of Azacitidine For Injection

Dr. Reddy’s Laboratories (NYSE: RDY) announced today that Azacitidine for Injection 100 mg/vial, a bioequivalent generic version of VIDAZA ® (azacitidine for injection), is approved by the United States Food ...

Ratings Changes Today

Upgrades: FSM, LND, RDY, SGMA Downgrades: ABMD, HOLX Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Infosys, Tata Ready for Takeoff

Infosys, Tata Ready for Takeoff

Indian exporters such as Infosys, Tata Motors and Dr. Reddy's are benefitting from global market trends, says Kunal Ghosh, Portfolio Manager for the AllianzGI Emerging Markets Opportunities Fund.

Dr. Reddy’s Announces The Launch Of Divalproex Sodium Extended - Release Tablets, USP

Dr. Reddy’s Announces The Launch Of Divalproex Sodium Extended - Release Tablets, USP

Dr. Reddy’s Laboratories (NYSE: RDY) announced today that it has launched Divalproex Sodium Extended - Release Tablets, USP (250 mg and 500 mg), a therapeutic equivalent generic version of Depakote ® ER...

Dr. Reddy’s Appoints Dr. Sripada Chandrasekhar As President And Global Head Of Human Resources

Dr. Reddy’s Appoints Dr. Sripada Chandrasekhar As President And Global Head Of Human Resources

Dr. Reddy’s has announced the appointment of Dr.

Ratings Changes To Be Publicly Issued on 8/1/13

Upgrades: ARE, BBOX, BFS, CAFI, ELGX, HT, LBY, LMNX, MAS, SEM, TFSL, UMH, VSB Downgrades: ADVS, RDY, UDR Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

3 Stocks Dragging In The Drugs Industry

3 Stocks Dragging In The Drugs Industry

TheStreet highlights 3 stocks pushing the drugs industry lower today.

Dr. Reddy’s Q1 FY14 Financial Results

Dr. Reddy’s Q1 FY14 Financial Results

Dr. Reddy’s Laboratories Ltd.

Dr. Reddy’s Announces The Launch Of Donepezil Hydrochloride Tablets, 23 Mg

Dr. Reddy’s Announces The Launch Of Donepezil Hydrochloride Tablets, 23 Mg

Dr. Reddy’s Laboratories (NYSE: RDY) announced yesterday that it has launched Donepezil Hydrochloride Tablets, 23 mg, a therapeutic equivalent generic version of ARICEPT ®, 23 mg in the U.

Dr. Reddy's To Release Q1 FY14 Results On July 30, 2013

Dr. Reddy's To Release Q1 FY14 Results On July 30, 2013

Dr. Reddy's Laboratories (NYSE: RDY) will announce results for the First Quarter ended June 30, 2013 on Tuesday, July 30, 2013 after the Board Meeting.

Dr. Reddy’s Laboratories Limited Announces Filing Of Annual Report On Form 20-F

Dr. Reddy’s Laboratories Limited Announces Filing Of Annual Report On Form 20-F

Dr. Reddy’s Laboratories Limited (NYSE: RDY) today announced that its Annual Report on Form 20-F, containing its annual consolidated financial statements for the fiscal year ended 31 March, 2013, was filed with the ...

Dr. Reddy’s Announces The Launch Of Decitabine For Injection

Dr. Reddy’s Announces The Launch Of Decitabine For Injection

Dr. Reddy’s Laboratories (NYSE: RDY) announced today that it has launched Decitabine for Injection (50mg) a therapeutic equivalent generic version of Dacogen ® (Decitabine for Injection) in the US market on...

5 Stocks Pushing The Drugs Industry Lower

5 Stocks Pushing The Drugs Industry Lower

TheStreet highlights 5 stocks pushing the drugs industry lower today.

Dr. Reddy’s Announces The Launch Of Lamotrigine Extended-Release Tablets

Dr. Reddy’s Announces The Launch Of Lamotrigine Extended-Release Tablets

Dr. Reddy’s Laboratories (NYSE: RDY) announced today that is has launched Lamotrigine Extended-Release Tablets (25 mg, 50 mg, 100 mg, 200 mg, 300 mg) a therapeutic equivalent generic version of Lamictal ® XR...

DVAX, RDY, ONXX, ALXN And VRX, 5 Health Care Stocks Pushing The Sector Lower

DVAX, RDY, ONXX, ALXN And VRX, 5 Health Care Stocks Pushing The Sector Lower

TheStreet Ratings group highlights 5 stocks pushing the health care sector lower today.

8 Stocks Surging on Big Volume

8 Stocks Surging on Big Volume

Often when above-average volume moves into an equity, it precedes a large spike in volatility.

4 Stocks Raising The Health Care Sector Higher

4 Stocks Raising The Health Care Sector Higher

TheStreet Ratings group highlights 4 stocks pushing the health care sector higher today.

Dr. Reddy’s And Nordion Inc. (formerly MDS Inc.) Settle Claims

Dr. Reddy’s And Nordion Inc. (formerly MDS Inc.) Settle Claims

Dr. Reddy’s Laboratories (NYSE: RDY) announced today that it had settled its claims against Nordion Inc.

Dr. Reddy’s Announces The Launch Of Zoledronic Acid Injection

Dr. Reddy’s Announces The Launch Of Zoledronic Acid Injection

Dr. Reddy’s Laboratories (NYSE: RDY) announced today that it has launched Zoledronic Acid Injection (4 mg/5 mL), a bioequivalent generic version of Zometa ® (zoledronic acid) 4 mg/5 mL Injection in the US...

TheStreet Quant Rating: C (Hold)